neurontin pain relief Biopharma Rally On Hold
This is not a good week for trading. Portfolio managers are re-jiggering positions so you may not see the trends correctly. Today there was much more red than green.Many biotech stocks started rallying off the bottom in October then again around December 11. There are many cross currents in the market so sit tight with your core positions and look for some direction in January during the J.P.Morgan Healthcare Conference beginning January 11, 2016. We gave our last update on December 11 for a tradeable bottom and it worked. Over the next two weeks we will review our focus stocks by sector YTD. The by mid-January we should have some new trends and picks for 2o16. We also plan to review some of the emerging mid-cap “hot stocks” of 2015 by technology: CAR-T, immuno-oncology, rare-diseases and RNAi.
Here is a preliminary review by size and sector:
- The Rayno http://research-consulting.com/2014/11/ large cap motif was up 5% YTD dragged down by Abbvie (ABBV) and Biogen (BIIB) down 10.5%. Regeneron (REGN) was up 31.7%. The IBB was up 11.17% to the $337 handle with a range of 284 to 401 for 2015.
- The Rayno buy provigil fast shipping mid-cap biopharma motif is up 31% YTD. Pharmacyclics (PCYC) was the big winner up 113.7% acquired at $20B + by Abbvie (ABBV). The big loser was Clovis Oncology (CLVS) down 41% because of disappointing clinical trial results. Alkermes (ALKS) and Seattle Genetics (SGEN) were big winners.
- The Rayno small cap picks did extremely well and would have done better until the severe market meltdown in August/September. Notable results YTD are Fibrocell Science (FCSC) up 79.9% and Ignyta (RXDX) up 34.4%. Since the October BIO Investor Forum all of our new picks are up: CRIS, GERN, OCRA. Although the small cap weighted S&P SPDR (XBI) is up 12% YTD at 69.7 it has topped out from the October bottom. These two stocks are not on our focus list but illustrate the binary nature of small caps picks: Chimerix (CMRX) rattled biotech stocks today with an astonishing 81% decline due to failure of its lead product brincidofovir in a Phase 3 study for cytomegalovirus (CMV) infection in patients undergoing hematopoietic cell transplantation. But last week Adamas Pharmaceuticals announced Positive Top Line results of a Phase 3 drug for the treatment of Levodopa induced Dyskinesia in patients with Parkinson’s disease. The stock surged 305 on December 23 on the news.
- Healthcare sector (XLV) up 5.45% YTD but “choppy and toppy” flat over one month, AND flat over one year.
Momentum has clearly left the market although the tape is still healthy because of good trading volume in selected stocks and the vast amounts of money participating with huge winnings over five years. IPOs have slowed to a trickle and mezzanine funding is harder to get. From a traders perspective we are in a bear market where speculative stock ideas are harder to find. Technicals matter the most for now until we launch into an upward channel. Our trading call of December 12 was positive so hold onto core positions.
NEXT UP in future POSTS:
Rayno Life Science Portfolio Winners and Losers
Rayno Diagnostics and Tools 2015 Review
Trends to Watch in 2016
J.P. Morgan Healthcare Conference